Treatment with statins reduces mortality risk for patients taking effective HIV therapy
Ambulatory blood pressure monitoring shows that 15% of HIV patients had undiagnosed high blood pressure
Accelerated hardening of the arteries in patients with HIV; traditional risks the main cause
Boceprevir response and resistance differs according to HCV genotype 1 subtype
Cognitive impairment still common but ART reduces risk
Raltegravir combined with Kaletra associated with good preservation of bone density over 96 weeks
HPTN 052: early treatment reduces serious illness by 40%
Doubt remains if HIV therapy increases the risk of fragility fractures
Marker of cardiovascular disease also associated with bone problems in patients with HIV
